Actinic Keratosis Treatment Market is Anticipated to Grow US$ 10.12 Bn By 2030

The global Actinic Keratosis Treatment  market size is expected to reach USD 10.12 billion by 2030, registering a CAGR of 7.3% over the forecast period 2021 – 2030.

Download Exclusive Sample of Report@ https://www.visionresearchreports.com/report/sample/38605

Growth Factors

 The increasing prevalence of the disease coupled with an increasing geriatric population and rising awareness about the disease are factors expected to drive the growth over the forecast period. For instance, in the U.S. and Europe, the prevalence of the disease ranges from 11 to 26%, due to which it is the most commonly treated dermatologic disease in the outpatient setting in the U.S. Moreover, the prevalence is highest in Australia with an estimation of 37 to 55% in adults aged 40 years and above. However, the outbreak of COVID-19 has affected the market adversely.

Report Coverage

Report Scope Details
Market Size USD 10.12 billion by 2030
Growth Rate CAGR of 7.3% From 2021 to 2030
Base Year 2021
Historic Data 2017 to 2020
Forecast Period 2021 to 2030
Segments Covered Therapy, Drug class, End-use
Regional Scope North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Companies Mentioned Almirall, S.A.; Biofrontera AG; Bausch Health Companies, Inc.; LEO Pharma A/S; Sun Pharmaceutical Industries Ltd.; Novartis AG; GALDERMA; Hill Dermaceuticals, Inc.

Report Highlights

The surgical therapy segment dominated the global market in 2020 with a revenue share of more than 67%. The segment is anticipated to maintain its dominance over the forecast period. The high penetration of cryotherapy for the treatment of AK will drive the segment growth. This is also called field therapy and has a low associated risk of scarring. The photodynamic therapy segment is anticipated to grow at a CAGR of 7.10% over the forecast period.

The nucleoside metabolic inhibitors drug class segment led the global market in 2020 with a revenue share of over 32%. The growth was driven by the strong commercial performances of Carac, Efudex, and Fluoroplex. Moreover, increasing awareness about diagnostics and treatment strategies for this disease has driven the widespread adoption of field-directed treatments, such as 5-fluorouracil.

The photo-enhancers segment is estimated to witness the fastest CAGR during the forecast period. Photodynamic therapy is gaining ground and is expected to positively impact the market growth of photo-enhancers.

The photo-enhancers segment is estimated to witness the fastest CAGR during the forecast period. Photodynamic therapy is gaining ground and is expected to positively impact the market growth of photo-enhancers.

The home care segment is anticipated to grow at the fastest CAGR over the forecast period. Increasing adoption of topical therapies, availability of OTC drugs, and patient convenience are factors driving the segment growth over the forecast period.

North America accounted for the highest revenue share of more than 42% of the global market in 2020. It is anticipated to maintain its dominance over the forecast period.

Asia Pacific is estimated to grow at the fastest CAGR over the forecast period due to an increase in the treatment rate of the disease, rising consumer disposable income, and high disease prevalence in certain countries, such as Australia and New Zealand.

Key Players

  • Sun Pharmaceutical Industries Ltd.
  • Novartis AG
  • GALDERMA
  • Hill Dermaceuticals, Inc.
  • Viatris Inc.
  • Mylan N.V.
  • Bausch Health Companies, Inc.
  • LEO Pharma A/S
  • Almirall, S.A.
  • Biofrontera AG
  • 3M

Market Segmentation

  • Therapy
    • Topical
    • Surgery
    • Photodynamic Therapy
  • Drug Class
    • Nucleoside Metabolic Inhibitor
    • NSAIDs
    • Immune Response Modifiers
    • Photoenhancers
    • Others
  • End-use
    • Hospitals
    • Private Clinics
    • Homecare
    • Others
  • Regional
    • North America
      • U.S
      • Canada
    • Europe
      • U.K.
      • Germany
      • France
      • Italy
      • Spain
    • Asia Pacific
      • India
      • China
      • Japan
      • Australia
      • South Korea
    • Latin America
      • Argentina
      • Brazil
      • Mexico
    • Middle East & Africa
      • Saudi Arabia
      • UAE
      • South Africa

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38605

Reasons to Purchase this Report:

– Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
– Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
– Market value USD Million and volume Units Million data for each segment and sub-segment
– Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
– Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players

Table of Contents

Chapter 1.  Introduction

1.1.  Research Objective

1.2.  Scope of the Study

1.3.  Definition

Chapter 2.  Research Methodology

2.1.  Research Approach

2.2.  Data Sources

2.3.  Assumptions & Limitations

Chapter 3.  Executive Summary

3.1.  Market Snapshot

Chapter 4.  Market Variables and Scope

4.1.  Introduction

4.2.  Market Classification and Scope

4.3.  Industry Value Chain Analysis

4.3.1.    Raw Material Procurement Analysis

4.3.2.    Sales and Distribution Channel Analysis

4.3.3.    Downstream Buyer Analysis

Chapter 5.  Market Dynamics Analysis and Trends

5.1.  Market Dynamics

5.1.1.    Market Drivers

5.1.2.    Market Restraints

5.1.3.    Market Opportunities

5.2.  Porter’s Five Forces Analysis

5.2.1.    Bargaining power of suppliers

5.2.2.    Bargaining power of buyers

5.2.3.    Threat of substitute

5.2.4.    Threat of new entrants

5.2.5.    Degree of competition

Chapter 6.  Competitive Landscape

6.1.1.    Company Market Share/Positioning Analysis

6.1.2.    Key Strategies Adopted by Players

6.1.3.    Vendor Landscape

6.1.3.1.        List of Suppliers

6.1.3.2.        List of Buyers

Chapter 7.  Global Actinic Keratosis Treatment Market, By Therapy

7.1.  Actinic Keratosis Treatment Market, by Therapy, 2021-2030

7.1.1.    Topical

7.1.1.1.        Market Revenue and Forecast (2017-2030)

7.1.2.    Surgery

7.1.2.1.        Market Revenue and Forecast (2017-2030)

7.1.3.    Photodynamic Therapy

7.1.3.1.        Market Revenue and Forecast (2017-2030)

Chapter 8.  Global Actinic Keratosis Treatment Market, By Drug Class

8.1.  Actinic Keratosis Treatment Market, by Drug Class, 2021-2030

8.1.1.    Nucleoside Metabolic Inhibitor

8.1.1.1.        Market Revenue and Forecast (2017-2030)

8.1.2.    NSAIDs

8.1.2.1.        Market Revenue and Forecast (2017-2030)

8.1.3.    Immune Response Modifiers

8.1.3.1.        Market Revenue and Forecast (2017-2030)

8.1.4.    Photoenhancers

8.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 9.  Global Actinic Keratosis Treatment Market, By End User

9.1.  Actinic Keratosis Treatment Market, by End User, 2021-2030

9.1.1.    Hospitals

9.1.1.1.        Market Revenue and Forecast (2017-2030)

9.1.2.    Private Clinics

9.1.2.1.        Market Revenue and Forecast (2017-2030)

9.1.3.    Homecare

9.1.3.1.        Market Revenue and Forecast (2017-2030)

9.1.4.    Others

9.1.4.1.        Market Revenue and Forecast (2017-2030)

Chapter 10.      Global Actinic Keratosis Treatment Market, Regional Estimates and Trend Forecast

10.1.        North America

10.1.1.  Market Revenue and Forecast, by Therapy (2017-2030)

10.1.2.  Market Revenue and Forecast, by Drug Class (2017-2030)

10.1.3.  Market Revenue and Forecast, by End User (2017-2030)

10.1.4.  U.S.

10.1.4.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.1.4.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.1.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.1.5.  Rest of North America

10.1.5.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.1.5.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.1.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.        Europe

10.2.1.  Market Revenue and Forecast, by Therapy (2017-2030)

10.2.2.  Market Revenue and Forecast, by Drug Class (2017-2030)

10.2.3.  Market Revenue and Forecast, by End User (2017-2030)

10.2.4.  UK

10.2.4.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.2.4.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.2.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.5.  Germany

10.2.5.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.2.5.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.2.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.6.  France

10.2.6.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.2.6.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.2.6.3.      Market Revenue and Forecast, by End User (2017-2030)

10.2.7.  Rest of Europe

10.2.7.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.2.7.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.2.7.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.        APAC

10.3.1.  Market Revenue and Forecast, by Therapy (2017-2030)

10.3.2.  Market Revenue and Forecast, by Drug Class (2017-2030)

10.3.3.  Market Revenue and Forecast, by End User (2017-2030)

10.3.4.  India

10.3.4.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.3.4.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.3.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.5.  China

10.3.5.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.3.5.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.3.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.6.  Japan

10.3.6.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.3.6.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.3.6.3.      Market Revenue and Forecast, by End User (2017-2030)

10.3.7.  Rest of APAC

10.3.7.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.3.7.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.3.7.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.        MEA

10.4.1.  Market Revenue and Forecast, by Therapy (2017-2030)

10.4.2.  Market Revenue and Forecast, by Drug Class (2017-2030)

10.4.3.  Market Revenue and Forecast, by End User (2017-2030)

10.4.4.  GCC

10.4.4.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.4.4.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.4.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.5.  North Africa

10.4.5.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.4.5.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.4.5.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.6.  South Africa

10.4.6.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.4.6.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.4.6.3.      Market Revenue and Forecast, by End User (2017-2030)

10.4.7.  Rest of MEA

10.4.7.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.4.7.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.4.7.3.      Market Revenue and Forecast, by End User (2017-2030)

10.5.        Latin America

10.5.1.  Market Revenue and Forecast, by Therapy (2017-2030)

10.5.2.  Market Revenue and Forecast, by Drug Class (2017-2030)

10.5.3.  Market Revenue and Forecast, by End User (2017-2030)

10.5.4.  Brazil

10.5.4.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.5.4.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.5.4.3.      Market Revenue and Forecast, by End User (2017-2030)

10.5.5.  Rest of LATAM

10.5.5.1.      Market Revenue and Forecast, by Therapy (2017-2030)

10.5.5.2.      Market Revenue and Forecast, by Drug Class (2017-2030)

10.5.5.3.      Market Revenue and Forecast, by End User (2017-2030)

Chapter 11.  Company Profiles

11.1.              Sun Pharmaceutical Industries Ltd.

11.1.1.  Company Overview

11.1.2.  Product Offerings

11.1.3.  Financial Performance

11.1.4.  Recent Initiatives

11.2.              Novartis AG

11.2.1.  Company Overview

11.2.2.  Product Offerings

11.2.3.  Financial Performance

11.2.4.  Recent Initiatives

11.3.              GALDERMA

11.3.1.  Company Overview

11.3.2.  Product Offerings

11.3.3.  Financial Performance

11.3.4.  Recent Initiatives

11.4.              Hill Dermaceuticals, Inc.

11.4.1.  Company Overview

11.4.2.  Product Offerings

11.4.3.  Financial Performance

11.4.4.  Recent Initiatives

11.5.              Viatris Inc.

11.5.1.  Company Overview

11.5.2.  Product Offerings

11.5.3.  Financial Performance

11.5.4.  Recent Initiatives

11.6.              Mylan N.V.

11.6.1.  Company Overview

11.6.2.  Product Offerings

11.6.3.  Financial Performance

11.6.4.  Recent Initiatives

11.7.              Bausch Health Companies, Inc.

11.7.1.  Company Overview

11.7.2.  Product Offerings

11.7.3.  Financial Performance

11.7.4.  Recent Initiatives

11.8.              LEO Pharma A/S

11.8.1.  Company Overview

11.8.2.  Product Offerings

11.8.3.  Financial Performance

11.8.4.  Recent Initiatives

11.9.              Almirall, S.A.

11.9.1.  Company Overview

11.9.2.  Product Offerings

11.9.3.  Financial Performance

11.9.4.  Recent Initiatives

11.10.           Biofrontera AG

11.10.1.               Company Overview

11.10.2.               Product Offerings

11.10.3.               Financial Performance

11.10.4.               Recent Initiatives

11.11.           3M

11.11.1.               Company Overview

11.11.2.               Product Offerings

11.11.3.               Financial Performance

11.11.4.               Recent Initiatives

Chapter 12.  Research Methodology

12.1.              Primary Research

12.2.              Secondary Research

12.3.              Assumptions

Chapter 13.  Appendix

13.1.              About Us

Glossary of Terms

Buy this Research Report study@ https://www.visionresearchreports.com/report/cart/38605

Contact Us:

Vision Research Reports

Call: +1 9197 992 333

Email: sales@visionresearchreports.com